Media and Investor Contact:
Jonae R. Barnes
Vice President
Investor Relations and Corporate Communications jonae.barnes@agenusbio.com
617-818-2985
Agenus to Present at OneMedForum San Francisco 2012
Lexington, MA - January 4, 2012 - Agenus Inc. (Nasdaq: AGEN),
a developer of therapeutic vaccines for cancer and infectious
diseases, today announced that the company will be presenting
at the 5th Annual OneMedForum San Francisco
2012, which will be held at the Sir Francis Drake Hotel in
San Francisco.
Dr. Garo Armen, Chairman and CEO of Agenus, will present a
corporate overview on Tuesday, January 10th from
9:15-9:30 am PST in the Windsor Room and a break out session
will follow from
9:30-10:15 am.
Between Agenus and its partners, 18 programs are in clinical
development. Agenus' QS-21
Stimulon® adjuvant* is being
studied in clinical trials for 15 vaccine indications. They
include:
• Phase 3: GSK's RTS,S for malaria
• Phase 3: GSK's MAGE-A3 for non-small cell lung cancer
• Phase 3: GSK's MAGE-A3 for melanoma
• Phase 3: GSK's Zoster Herpes for shingles
• Phase 2: Janssen's ACC-001 for Alzheimer's disease
Agenus pipeline programs include:
• Phase 2: Prophage Series G-100 for newly diagnosed glioma
• Phase 2: Prophage Series G-200 for recurrent glioma
• Phase 2 Ready: HerpV (contains QS-21 Stimulon) for genital herpes
Saponin Platform: QS-21 Stimulon® Adjuvant
Agenus' licensees include GlaxoSmithKline, Janssen Alzheimer Immunotherapy, and Integrated Biotherapeutics. Agenus is entitled to receive milestone payments as QS-21-containing programs advance, as well as royalties for 10 years after commercial launch.
Heat Shock Protein Platform: Prophage Series G
The Prophage Series G vaccines (HSPPC-96; vitespen) are being
studied in two different settings
of glioma: newly diagnosed and recurrent disease. Glioma is
the deadliest form of brain cancer with an average survival
of six to 14 months.
Heat Shock Protein Platform: Recombinant Series HerpV
HerpV is the most advanced HSV-2 vaccine currently in
clinical development for the treatment
of genital herpes. Agenus plans to advance HerpV into a Phase
2 study in 2012 that will measure the effect of vaccination
on viral shedding in individuals infected with HSV-2. Experts
in HSV-2
clinical research believe that a reduction in viral shedding
could translate into the clinical benefit of a reduction in
recurrent outbreaks.
Oncophage® Vaccine: Approved in Russia for Kidney Cancer
During the fourth quarter of 2011, Agenus and NewVac LLC (a
subsidiary of ChemRar),
announced a license, development and manufacturing technology
transfer agreement for Agenus' Oncophage (HSPPC-96; vitespen)
vaccine. Oncophage is approved in Russia for the
treatment
of renal cell carcinoma (kidney cancer) in patients at
intermediate risk of recurrence. Under the agreement, Agenus
has granted NewVac an exclusive license to manufacture,
market and sell Oncophage as well as pursue a development
program of Oncophage in combination with NewVac's co-adjuvant
technology in the Russian Federation and CIS countries.
Agenus is entitled to receive a transfer price and/or
royalties upon Oncophage product sales, and potential
milestone payments
Web Cast Information
The live and archived webcast of the company presentation
will be accessible from the
company's website
at www.agenusbio.com/webcast.
Please log in approximately 5-10 minutes before each event to
ensure a timely connection. The archived replay will be
available on the Agenus website for one month following the
conference.
About Agenus
Agenus Inc. is a biotechnology company working to develop
treatments for cancers and
infectious diseases. The company is focused on
immunotherapeutic products based on strong platform
technologies with multiple product candidates advancing
through the clinic, including several product candidates that
have advanced into late-stage clinical trials through
corporate partners. For more information, please visit www.agenusbio.com.
Forward-Looking Statement
This press release contains forward-looking statements,
including statements regarding up- coming presentations and
technologies, programs, and activities of the company and its
licensees. These forward-looking statements are subject to
risks and uncertainties that could cause actual results to
differ materially. These risks and uncertainties include,
among others, the factors described under the Risk Factors
section of our Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission for the period ended
September 30, 2011. Agenus cautions investors not to place
considerable reliance on the forward-looking statements
contained in this release. These statements speak only as of
the date of this document, and Agenus undertakes no
obligation to update or revise the statements. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement. Agenus'
business is subject to substantial risks and uncertainties,
including those identified above. When evaluating Agenus'
business and securities, investors should give careful
consideration to these risks and uncertainties.
*QS-21 Stimulon® adjuvant is an asset of Antigenics, Inc., a wholly owned subsidiary of Agenus Inc. Stimulon and Oncophage are registered trademarks of Agenus Inc. and its subsidiaries.
###
distribué par | Ce noodl a été diffusé par Agenus Inc. et initialement mise en ligne sur le site http://www.agenusbio.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-04 14:20:01 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
Documents associés | |
Agenus to Present at OneMedForum San Francisco 2012 |